Shannon Thyme Klinger is Chief Legal Officer of Moderna, Inc.. Currently has a direct ownership of 18,154 shares of MRNA, which is worth approximately $787,702. The most recent transaction as insider was on Sep 09, 2024, when has been sold 551 shares (Common Stock) at a price of $73.57 per share, resulting in proceeds of $40,537. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 18.2K
5.06% 3M change
151.61% 12M change
Total Value Held $787,702

Shannon Thyme Klinger Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 09 2024
SELL
Open market or private sale
$40,537 $73.57 p/Share
551 Reduced 2.95%
18,154 Common Stock
Sep 06 2024
BUY
Exercise of conversion of derivative security
-
1,139 Added 5.74%
18,705 Common Stock
Sep 03 2024
SELL
Open market or private sale
$8,776 $76.99 p/Share
114 Reduced 0.64%
17,566 Common Stock
Aug 30 2024
BUY
Exercise of conversion of derivative security
-
233 Added 1.3%
17,680 Common Stock
Aug 29 2024
SELL
Open market or private sale
$12,640 $78.03 p/Share
162 Reduced 0.92%
17,447 Common Stock
Aug 28 2024
SELL
Open market or private sale
$104,715 $79.39 p/Share
1,319 Reduced 7.09%
17,280 Common Stock
Aug 28 2024
BUY
Exercise of conversion of derivative security
-
329 Added 1.83%
17,609 Common Stock
Aug 27 2024
BUY
Exercise of conversion of derivative security
-
2,652 Added 12.48%
18,599 Common Stock
Jun 10 2024
SELL
Open market or private sale
$766,810 $148.09 p/Share
5,178 Reduced 24.51%
15,947 Common Stock
Jun 07 2024
BUY
Exercise of conversion of derivative security
-
10,247 Added 32.66%
21,125 Common Stock
Jun 03 2024
SELL
Open market or private sale
$17,167 $140.72 p/Share
122 Reduced 1.11%
10,878 Common Stock
May 31 2024
BUY
Exercise of conversion of derivative security
-
232 Added 2.07%
11,000 Common Stock
May 29 2024
SELL
Open market or private sale
$26,443 $144.5 p/Share
183 Reduced 1.67%
10,768 Common Stock
May 28 2024
SELL
Open market or private sale
$210,561 $162.47 p/Share
1,296 Reduced 10.87%
10,623 Common Stock
May 28 2024
BUY
Exercise of conversion of derivative security
-
328 Added 2.91%
10,951 Common Stock
May 24 2024
BUY
Exercise of conversion of derivative security
-
2,652 Added 18.2%
11,919 Common Stock
Mar 08 2024
SELL
Open market or private sale
$53,883 $99.05 p/Share
544 Reduced 5.54%
9,267 Common Stock
Mar 07 2024
BUY
Exercise of conversion of derivative security
-
1,138 Added 10.39%
9,811 Common Stock
Mar 04 2024
SELL
Open market or private sale
$11,037 $94.34 p/Share
117 Reduced 1.33%
8,673 Common Stock
Mar 01 2024
BUY
Exercise of conversion of derivative security
-
233 Added 2.58%
8,790 Common Stock
Feb 29 2024
SELL
Open market or private sale
$63,361 $94.57 p/Share
670 Reduced 7.26%
8,557 Common Stock
Feb 28 2024
BUY
Exercise of conversion of derivative security
-
1,315 Added 12.47%
9,227 Common Stock
Dec 08 2023
SELL
Open market or private sale
$44,527 $79.09 p/Share
563 Reduced 6.64%
7,912 Common Stock
Dec 07 2023
BUY
Exercise of conversion of derivative security
-
1,139 Added 11.85%
8,475 Common Stock
Dec 04 2023
SELL
Open market or private sale
$8,803 $79.31 p/Share
111 Reduced 1.49%
7,336 Common Stock

Also insider at

RFL
Rafael Holdings, Inc. Real Estate
STK

Shannon Thyme Klinger

Chief Legal Officer
Cambridge, MA

Track Institutional and Insider Activities on MRNA

Follow Moderna, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRNA shares.

Notify only if

Insider Trading

Get notified when an Moderna, Inc. insider buys or sells MRNA shares.

Notify only if

News

Receive news related to Moderna, Inc.

Track Activities on MRNA